Author

A. Korkut

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Approach:statistical model· 4 Research Focus:differential expression· 3 Research Focus:gene regulatory network inference· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:multiome· 2

Frequent Co-Authors

B. Bozorgui· 3 shared X. Li· 3 shared A. Luna· 2 shared C. Sander· 2 shared G. Yan· 2 shared O. Babur· 2 shared Z. Dereli· 2 shared A. Can· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

B. Bozorgui

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Exploring the genome-wide expression level of the bacterial strain belonging to Bacillus safensis (MM19) against Phomopsis viticola

O. Baysal, R. S. Silme, A. Can, Y. Kurum, A. Korkut, K. K. KIRBOGA, A. Cetinkaya

The paper investigates the genome-wide gene expression of Bacillus safensis strain MM19 against Phomopsis viticola, identifying thiamine biosynthesis and virulence gene expression changes.

bioRxiv · May 3, 2024 · PreprintMicrobiology

A prognostic matrix code defines functional glioblastoma phenotypes and niches.

M. Vishnoi, Z. Dereli, Z. Yin, E. K. Kong, M. Kinali, K. Thapa, O. Babur, K. Yun, N. H. Abdelfattah, X. Li, B. Bozorgui, R. C. Rostomily, A. Korkut

This paper identifies a matrix code based on extracellular core matrix proteins that categorizes glioblastoma tumors into prognostic groups and predicts responses to PD1 blockade.

bioRxiv · Jun 6, 2023 · PreprintCancer Biology

Precision combination therapies based on recurrent oncogenic co-alterations

X. Li, E. Dowling, G. Yan, B. Bozorgui, P. Imanirad, J. H. Elnaggar, A. Luna, C. Sander, A. Korkut

The paper develops REFLECT, a method that maps recurrent co-alteration signatures to drug combinations using multi-omic data, validating its effectiveness across 201 cohorts and 10,392 patients.

bioRxiv · Jun 3, 2020Cancer Biology

BET inhibition induces an anti-apoptotic adaptive response and therapeutic vulnerability to MCL1 inhibitors in breast cancer

G. Yan, H. Wang, A. Luna, B. Bozorgui, X. Li, Z. Dereli, X. Chen, Y. Lu, O. Babur, C. Sander, G. Mills, A. Korkut

This study shows BET inhibition in breast cancer triggers an anti-apoptotic response via MCL1 upregulation, and co-targeting BET and MCL1 is synergistic and effective in basal-like breast cancers.

bioRxiv · Mar 21, 2020Cancer Biology